000910743 001__ 910743
000910743 005__ 20221219115102.0
000910743 0247_ $$2doi$$a10.1016/j.dadm.2019.01.011
000910743 0247_ $$2Handle$$a2128/32629
000910743 0247_ $$2pmid$$a30984816
000910743 0247_ $$2WOS$$aWOS:000723892800035
000910743 037__ $$aFZJ-2022-04113
000910743 082__ $$a610
000910743 1001_ $$0P:(DE-HGF)0$$aEimeren, Thilo$$b0$$eCorresponding author
000910743 245__ $$aNeuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System
000910743 260__ $$aHoboken, NJ$$bWiley$$c2019
000910743 3367_ $$2DRIVER$$aarticle
000910743 3367_ $$2DataCite$$aOutput Types/Journal article
000910743 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1668667532_3489
000910743 3367_ $$2BibTeX$$aARTICLE
000910743 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000910743 3367_ $$00$$2EndNote$$aJournal Article
000910743 520__ $$aIntroductionTherapeutic strategies targeting protein aggregations are ready for clinical trials in atypical parkinsonian disorders. Therefore, there is an urgent need for neuroimaging biomarkers to help with the early detection of neurodegenerative processes, the early differentiation of the underlying pathology, and the objective assessment of disease progression. However, there currently is not yet a consensus in the field on how to describe utility of biomarkers for clinical trials in atypical parkinsonian disorders.MethodsTo promote standardized use of neuroimaging biomarkers for clinical trials, we aimed to develop a conceptual framework to characterize in more detail the kind of neuroimaging biomarkers needed in atypical parkinsonian disorders, identify the current challenges in ascribing utility of these biomarkers, and propose criteria for a system that may guide future studies.ResultsAs a consensus outcome, we describe the main challenges in ascribing utility of neuroimaging biomarkers in atypical parkinsonian disorders, and we propose a conceptual framework that includes a graded system for the description of utility of a specific neuroimaging measure. We included separate categories for the ability to accurately identify an intention-to-treat patient population early in the disease (Early), to accurately detect a specific underlying pathology (Specific), and the ability to monitor disease progression (Progression).DiscussionWe suggest that the advancement of standardized neuroimaging in the field of atypical parkinsonian disorders will be furthered by a well-defined reference frame for the utility of biomarkers. The proposed utility system allows a detailed and graded description of the respective strengths of neuroimaging biomarkers in the currently most relevant areas of application in clinical trials.Keywords: Biomarker, Trials, PSP, MSA, CBD, CBS, Neurodegeneration, Biomarker, Multicentric, Multisite, Neuroimaging, Harmonization, PET, MRI
000910743 536__ $$0G:(DE-HGF)POF4-899$$a899 - ohne Topic (POF4-899)$$cPOF4-899$$fPOF IV$$x0
000910743 588__ $$aDataset connected to CrossRef, Journals: juser.fz-juelich.de
000910743 7001_ $$0P:(DE-HGF)0$$aAntonini, Angelo$$b1
000910743 7001_ $$0P:(DE-HGF)0$$aBerg, Daniela$$b2
000910743 7001_ $$0P:(DE-HGF)0$$aBohnen, Nico$$b3
000910743 7001_ $$0P:(DE-HGF)0$$aCeravolo, Roberto$$b4
000910743 7001_ $$0P:(DE-Juel1)177611$$aDrzezga, Alexander$$b5
000910743 7001_ $$0P:(DE-HGF)0$$aHöglinger, Günter U.$$b6
000910743 7001_ $$0P:(DE-HGF)0$$aHiguchi, Makoto$$b7
000910743 7001_ $$0P:(DE-HGF)0$$aLehericy, Stephane$$b8
000910743 7001_ $$0P:(DE-HGF)0$$aLewis, Simon$$b9
000910743 7001_ $$0P:(DE-HGF)0$$aMonchi, Oury$$b10
000910743 7001_ $$0P:(DE-HGF)0$$aNestor, Peter$$b11
000910743 7001_ $$0P:(DE-HGF)0$$aOndrus, Matej$$b12
000910743 7001_ $$0P:(DE-HGF)0$$aPavese, Nicola$$b13
000910743 7001_ $$0P:(DE-HGF)0$$aPeralta, María Cecilia$$b14
000910743 7001_ $$0P:(DE-HGF)0$$aPiccini, Paola$$b15
000910743 7001_ $$0P:(DE-HGF)0$$aPineda-Pardo, José Ángel$$b16
000910743 7001_ $$0P:(DE-HGF)0$$aRektorová, Irena$$b17
000910743 7001_ $$0P:(DE-HGF)0$$aRodríguez-Oroz, María$$b18
000910743 7001_ $$0P:(DE-HGF)0$$aRominger, Axel$$b19
000910743 7001_ $$0P:(DE-HGF)0$$aSeppi, Klaus$$b20
000910743 7001_ $$0P:(DE-HGF)0$$aStoessl, A. Jon$$b21
000910743 7001_ $$0P:(DE-HGF)0$$aTessitore, Alessandro$$b22
000910743 7001_ $$0P:(DE-HGF)0$$aThobois, Stephane$$b23
000910743 7001_ $$0P:(DE-HGF)0$$aKaasinen, Valtteri$$b24
000910743 7001_ $$0P:(DE-HGF)0$$aWenning, Gregor$$b25
000910743 7001_ $$0P:(DE-HGF)0$$aSiebner, Hartwig R.$$b26
000910743 7001_ $$0P:(DE-HGF)0$$aStrafella, Antonio P.$$b27
000910743 7001_ $$0P:(DE-HGF)0$$aRowe, James B.$$b28
000910743 773__ $$0PERI:(DE-600)2832898-X$$a10.1016/j.dadm.2019.01.011$$gVol. 11, no. 1, p. 301 - 309$$n1$$p301 - 309$$tAlzheimer's & dementia / Diagnosis, assessment & disease monitoring$$v11$$x2352-8729$$y2019
000910743 8564_ $$uhttps://juser.fz-juelich.de/record/910743/files/FZJ-2022-04113_Neuroimaging%20biomarkers%20for%20clinical_2019.pdf$$yOpenAccess
000910743 909CO $$ooai:juser.fz-juelich.de:910743$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Multimodal Neuroimaging, Department of Nuclear Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany$$b0
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a German Centre for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany$$b0
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neuroscience, University of Padua, Padua, Italy$$b1
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, UKSH, Campus Kiel, Christian-Albrechts-University, Kiel, Germany$$b2
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Division of Nuclear Medicine, Department of Radiology, University of Michigan, and VAMC, Ann Arbor, MI, USA$$b3
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, University of Michigan, Ann Arbor, MI, USA$$b3
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a VAMC, Ann Arbor, MI, USA$$b3
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy$$b4
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a Multimodal Neuroimaging, Department of Nuclear Medicine, Medical Faculty and University Hospital, University of Cologne, Cologne, Germany$$b5
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a German Centre for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany$$b5
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-Juel1)177611$$a Forschungszentrum Jülich, INM-2, Jülich, Germany$$b5
000910743 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)177611$$aForschungszentrum Jülich$$b5$$kFZJ
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a National Institutes for Quantum and Radiological Science and Technology, Chiba, Japan$$b7
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Institut du Cerveau et de la Moelle épinière – ICM, Centre de NeuroImagerie de Recherche – CENIR, ICM Team “Movement Investigations and Therapeutics”, Sorbonne Universités, Inserm U1127, CNRS UMR, Paris, France$$b8
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Brain & Mind Centre, Sydney Medical School, University of Sydney, Sydney, NSW, Australia$$b9
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Clinical Neurosciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada$$b10
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Radiology, Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada$$b10
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Queensland Brain Institute, University of Queensland, Brisbane, QLD, Australia$$b11
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Mater Hospital, South Brisbane, QLD, Australia$$b11
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a AXON Neuroscience CRM Services SE, Bratislava, Slovak Republic$$b12
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Newcastle Magnetic Resonance Centre & Positron Emission Tomography Centre, Newcastle University, Newcastle upon Tyne, United Kingdom$$b13
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Center for Medical Education and Clinical Research, Section of Neurology, Buenos Aires, Argentina$$b14
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Medicine, Imperial College London, London, United Kingdom$$b15
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a hmCINAC, University Hospital HM Puerta del Sur, CEU-San Pablo University, Móstoles, Madrid, Spain$$b16
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a First Department of Neurology – Faculty of Medicine and CEITEC MU, Masaryk University, Brno, Czech Republic$$b17
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Clinica Universidad de Navarra, Pamplona, Spain$$b18
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Nuclear Medicine, Inselspital, Universitätsspital Bern, Bern, Switzerland$$b19
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria$$b20
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Pacific Parkinson’s Research Centre, University of British Columbia, Vancouver, Canada$$b21
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Medical, Surgery, Neurological, Metabolic and Aging Sciences, University of Campania, “L. Vanvitelli”, Caserta CE, Italy$$b22
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Université de Lyon, Université Claude Bernard Lyon 1, Faculté de Medecine Lyon Sud Charles Merieux, Lyon, France$$b23
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Hospices Civils de Lyon, Hopital Neurologique Pierre Wertheimer, Neurologie C, Lyon, France$$b23
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a CNRS, Institut des Sciences Cognitives, Bron, France$$b23
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Neurology, University of Turku, Turku, Finland$$b24
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Division of Clinical Neurosciences, Turku University Hospital, Turku, Finland$$b24
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Division of Clinical Neurology, Department of Neurology, Medical University of Innsbruck, Innsbruck, Austria$$b25
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Danish Research Centre for Magnetic Resonance, Copenhagen University Hospital Hvidovre, Hvidovre, Denmark$$b26
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Research Imaging Centre, Campbell Family Mental Health Research Institute, CAMH, Toronto, Ontario, Canada$$b27
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a lUniversity of Toronto, Toronto, Ontario, Canada$$b27
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a E.J. Safra Parkinson Disease Program, Toronto Western Hospital & Krembil Research Institute, UHN, Toronto, Ontario, Canada$$b27
000910743 9101_ $$0I:(DE-HGF)0$$6P:(DE-HGF)0$$a Department of Clinical Neurosciences, University of Cambridge, Cambridge, United Kingdom Thilo van Eimeren: thilo.van-eimeren@uk-koeln.de$$b28
000910743 9131_ $$0G:(DE-HGF)POF4-899$$1G:(DE-HGF)POF4-890$$2G:(DE-HGF)POF4-800$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bProgrammungebundene Forschung$$lohne Programm$$vohne Topic$$x0
000910743 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-09-09
000910743 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000910743 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-09-09
000910743 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-09-09
000910743 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000910743 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-09-09
000910743 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-09-09
000910743 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-09-09
000910743 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-09-09
000910743 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-09-09
000910743 920__ $$lyes
000910743 9201_ $$0I:(DE-Juel1)INM-2-20090406$$kINM-2$$lMolekulare Organisation des Gehirns$$x0
000910743 980__ $$ajournal
000910743 980__ $$aVDB
000910743 980__ $$aUNRESTRICTED
000910743 980__ $$aI:(DE-Juel1)INM-2-20090406
000910743 9801_ $$aFullTexts